Update on Inventiva’s cash position and on the finance documentation with the European Investment Bank
Daix (France), Long Island City (New York, United States), July 4, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced the strengthening of its cash position by approximately €14.6 million through its At-The-Market program (the “ATM Program”) and new state-backed bank financing. This extends the Company’s cash runway until the end of the second quarter 2023, based on existing cash, cash equivalents and short-term deposits and without taking into account the credit facility with the European Investment Bank (the “EIB”). The Company also finalized the documentation requirement under the credit facility with the EIB (the “Finance Contract”) for up to €50 million as announced on May 16, 2022 by the signing of a warrant agreement (the “Warrant Agreement”). The Company plans to use the proceeds from the EIB facility towards its preclinical and clinical pipeline, including to help fund a portion of its Phase III clinical trial of lanifibranor in patients with NASH.